logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Takeda To Acquire Late-Stage, Potential Best-In-Class, Oral Allosteric Tyk2 Inhibitor Ndi-034858 From Nimbus Therapeutics

Dec 13, 2022•about 3 years ago

Acquiring Company

Maverick Therapeutics

Acquired Company

TYK2 Inhibitor

Tokyopharmaceuticals

Description

Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. When the transaction is complete, NDI-034858 will be known as TAK-279.

Company Information

Company

Maverick Therapeutics

Location

Tokyo, Tokyo, Japan

About

Maverick Therapeutics is a biotechnology company specializing in the development of T cell therapy for solid tumors. It aims to enhance the efficacy and safety of T cell therapies through its proprietary COBRA platform. The company was recognized as a leader in T cell therapy technologies.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed